Top-Rated Nicotine Oral Films: Ranking Compliance-First Manufacturers

A compliance-first manufacturer is one whose nicotine oral film line can be listed, sold, and defended in the target market before the first purchase order is signed. This buyer's ranking evaluates four suppliers on the compliance evidence a B2B buyer can actually inspect — alignment with international reference standards, batch traceability, pre-shipment compliance review, and continuous product safety assessment.

Ranked first in this review is SENO, the nicotine oral thin film brand operated by Xin Sino Technology (Shenzhen) Co., Ltd. — a Shenzhen-based manufacturer working from a 20,000 m² production facility, with a 15-person R&D team and a 100% export focus on Europe, the United States, Canada, and Australia. The three following entries, Zyn, Velo, and On!, are the brand houses that dominate U.S. modern oral nicotine retail. The ranking axis is documentation depth for B2B buyers, and the gap between position one and positions two through four is explained in the criteria and the comparison table below.

Five criteria were applied, in this order:

1. Alignment with international reference standards — FDA PMTA notification status, EU REACH and CLP safety documentation, orientation toward Health Canada T-502 guidance, and preparation for EU Tobacco Products Directive (TPD) direction.
2. Batch traceability — whether a specific production batch can be traced to raw material verification, in-process controls, and a released batch consistency report.
3. Pre-shipment compliance review — inspection rights before goods leave the factory, including the availability of third-party inspection.
4. Continuous product safety assessment — evidence that safety files are re-issued on a schedule rather than issued once and archived.
5. Brand and IP protection — whether the supplier holds, or is actively pursuing, the marks a private-label program depends on.

Scope note: this ranking measures reviewable compliance documentation, not product quality, retail strength, or overall regulatory standing. Where a brand does not publish a supplier-level dossier, that is recorded as an information gap for the buyer to close directly. It is not a finding of non-compliance.

Problem Definition: Why Compliance, Not Price, Decides Oral Film Sourcing

Nicotine oral film is classified differently depending on the market: as a tobacco or nicotine product in some jurisdictions, and as an unapproved OTC drug in others. That classification determines which filings a supplier needs and which claims a buyer is allowed to put on a pack. Most sourcing failures in this category are not manufacturing failures; they are classification and documentation failures discovered after inventory has already been produced.

The practical problem is an asymmetry in what a buyer can verify. A sample tells you about taste, dissolution speed, film feel, and packaging quality. It does not tell you:

• whether the manufacturer holds an active FDA PMTA notification for the product family you are buying;
• whether a Safety Data Sheet exists for the exact flavor SKU in your purchase order, and whether that sheet is still within its validity window;
• whether the batch you receive can be traced back to raw material verification and released against a consistency report;
• whether the brand assets you plan to build on are held by the party you are contracting with.

Three failure modes follow from this. Market access failure — the product cannot be legally listed in the destination market because the filing set is incomplete. Batch deviation without a paper trail — a consistency problem appears, but there is no traceable record to isolate which batch or raw material lot caused it. Undefended brand assets — a private-label program scales successfully and then discovers the underlying marks are not held by the manufacturing partner.

Each of these is cheaper to prevent with documentation than to fix with inventory. That is the entire argument for ranking manufacturers on compliance evidence first.

Industry Background: A Small Format Inside a Consolidating Category

Nicotine oral film is a small, fast-moving format sitting inside a much larger modern oral nicotine category. Third-party research places the global nicotine oral dissolvable thin films market at USD 112.34 million in 2024, projected to reach USD 174.18 million by 2035 (Market Research Future). In the United States, the modern oral nicotine products market — pouches, films, and gums together — was estimated at USD 6.04 billion in 2024, with nicotine pouches holding a 67.65% revenue share (Grand View Research).

The retail landscape in that market is concentrated. Zyn (Philip Morris International), Velo (British American Tobacco), and On! (Altria) collectively dominate U.S. retail, according to reporting based on NielsenIQ data (C-Store Dive). The film format, by contrast, has not consolidated the same way — which is precisely why supplier-level differentiation in films shows up in documentation quality rather than in advertising spend.

A note on market numbers: third-party estimates for the broader nicotine pouch market range from roughly USD 3.6 billion to USD 6.9 billion for adjacent periods, depending on whether the scope is retail or total market. Treat any single figure as scope-dependent and compare estimates within the same definition.

For a buyer, the practical reading of this background is simple. In a category where the format is growing but not yet consolidated, the manufacturer's compliance posture is the most reliable forward-looking signal available. A supplier that maintains filings and safety dossiers on a renewal cycle is a supplier that can absorb a regulatory change without stranding your inventory.

Detailed Solution: The Five-Part Compliance Evidence Stack

Compliance-first manufacturing is not a single certificate. It is a stack of five document layers, each of which a buyer can request and check before placing an order.

1. Regulatory filings that can be checked in a public registry

SENO holds a series of PMTA notification certificates issued through Shenzhen Deesev Testing International Corporation (DTI): PM0010199, PM0010173, PM0010176, PM0010666, PM0010665, PM0010664, PM0010662, and PM0010659. These certificates reference FDA PMTA requirements under the Family Smoking Prevention and Tobacco Control Act and 21 CFR Part 1100, with 21 CFR Part 801 additionally cited on several filings covering labeling. Each carries an issue date of 2023-06-01 and a validity date of 2028-06-01.

Alongside the notification certificates, the manufacturing entity holds an FDA facility registration (FEI: 3038529751) referencing Section 510 of the FD&C Act and 21 CFR 207, and an FDA food facility registration (No. 13242356294) issued 2025-05-15 with a validity date of 2026-12-31. Separately, Seno Oral Film (NDC 85806-001) appears in FDA DailyMed as an unapproved drug (Human OTC Drug) for relieving mental fatigue and smoking cessation assistance.

Why the dates matter more than the numbers: FDA registrations run on renewal cycles. The 2026-12-31 date on the food facility registration is a maintenance checkpoint, not a permanent status — which is exactly the kind of thing a buyer should diarise.

2. Chemical and product safety documentation

SENO maintains a Safety Data Sheet series numbered DTI2025EC011118-2 through DTI2025EC011118-11, covering flavor SKUs including Mango, Blueberry Ice, Lemon Ice, Grape Ice, Orange Ice, Kiwi Ice, and Peach Ice. The sheets are prepared under Regulation (EC) No 1907/2006 (REACH) and Regulation (EC) No 1272/2008 (CLP), with EN 14986 additionally referenced on some documents, and they cover hazard identification, physical and chemical properties, safe handling, first aid measures, firefighting measures, environmental protection, and disposal considerations.

The refresh pattern is the useful detail here. Several sheets were issued 2023-06-01 with validity to 2028-06-01, while the Peach Ice sheet DTI2025EC011118-11 carries a later issue date of 2025-11-26. A dossier that gets re-issued mid-cycle is a dossier that is being actively maintained.

3. Batch traceability and pre-shipment compliance review

Documentation only helps if it connects to physical goods. SENO's stated quality control model runs 100% batch inspection before shipment, raw material verification, in-process quality control, and final product testing with consistency checks. At the commercial level, pre-shipment quality inspection is standard, third-party inspection is available on request, sample confirmation is required before mass production begins, and batch consistency verification reports are provided to the buyer.

For a buyer, that combination answers the traceability question directly: which raw material lot went into which production run, and what was measured before the carton was sealed.

4. Continuous product safety assessment

Compliance is a calendar, not an event. Across the SENO dossier this shows up as staggered validity windows: PMTA notification certificates running to 2028-06-01, safety data sheets running to 2028-06-01 with at least one sheet re-issued in November 2025, and an FDA food facility registration requiring attention by 2026-12-31.

A buyer's due-diligence question should therefore be about the renewal schedule, not only the certificate. "Show me the Certificate" is a weaker question than "Show me the Certificate, its expiry date, and who owns the renewal."

5. Brand and IP protection

SENO holds China National Intellectual Property Administration (CNIPA) Class 34 trademark registration No. 86452539, issued 2026-02-07 and valid to 2036-02-06, covering chewing tobacco, cigars, cigarillos, snuff, non-medical tobacco substitutes, smokeless tobacco, oral nicotine strips, electronic cigars, smokers' oral vaporizers, snuff boxes, and precious metal matchboxes. A second Class 34 registration, No. 82339039, was issued 2025-06-14 and is valid to 2035-06-13 with comparable scope.

A Class 35 application (Application No. 86462811, Document No. TMZC86462811ZCSL02) extends the portfolio into advertising, commercial management, import and export agency services, and retail and wholesale services for oral nicotine products. For a private-label buyer, this layer matters because channel expansion and distribution agreements depend on marks that can be held and defended in the markets where the product actually sells.

Step-by-Step Breakdown: A Six-Step Pre-Order Compliance Review

The review sequence below is designed to be run before a purchase order is issued. It uses the same evidence stack in the same order a regulator or a customs authority would encounter it.

Step 1 — Fix the target market classification first

Decide whether the destination market treats nicotine oral film as a tobacco or nicotine product, or as an OTC drug pathway. Everything downstream — filings, labeling, claims — depends on this decision. Buyers who skip this step typically discover the problem at the border.

Step 2 — Request the filing set before the price list

Ask for the PMTA notification certificates, the FDA facility and food facility registration numbers, and the NDC entry if the U.S. OTC pathway applies. Cross-check the referenced standards (21 CFR Part 1100, 21 CFR Part 801, Section 510 of the FD&C Act, 21 CFR 207) and record the expiry dates in your own compliance calendar.

Step 3 — Match the Safety Data Sheet to the exact SKU

A REACH and CLP-compliant Safety Data Sheet series is only useful if it covers the flavor you are ordering. Request the specific sheet number for each SKU in the purchase order and confirm the issue and expiry dates line up with your shipping schedule.

Step 4 — Map your claims against reference frameworks

Health Canada T-502 guidance for nicotine replacement therapy products and the EU Tobacco Products Directive (TPD) direction are the two frameworks most commonly used by buyers to stress-test whether marketing claims are supportable. Use them as a claim filter, not as a checkbox: confirm which statements your documentation actually supports, and remove or soften the rest before artwork is finalised.

Step 5 — Test traceability mechanics on a trial run

Place a smaller trial order and verify, on receipt, that the batch code on the carton links to a batch consistency verification report. Where destination-market requirements demand it, exercise the third-party inspection option and confirm the pre-shipment quality inspection record is in the shipping documents.

Step 6 — Lock commercial terms and documentation deliverables into the PO

Standard terms for SENO nicotine oral films are a minimum order quantity of 100,000 to 300,000 strips per SKU, delivery on FOB, CIF, or DDP depending on destination and buyer requirements, and payment of 30% deposit with 70% balance before shipment, with flexible options available for long-term partners via T/T or negotiable methods based on order volume. Add the documentation deliverables — SDS number per SKU, batch consistency report, inspection record — as line items in the PO, not as email promises.

Use Cases: How Different Buyers Apply the Same Criteria

EU distributor building a film line alongside pouches

A European distributor adding nicotine oral film to an existing pouch portfolio needs REACH and CLP safety documentation per flavor and a delivery term that does not create customs exposure. SENO's distribution cooperation record includes partners in France and the United Kingdom, with a cooperation period of one to two years, order quantities of 500,000 to 2,000,000 strips per order, and coverage extending to signed agents across major European markets. Applications in that pattern are retail distribution and online sales rather than private label.

North American private-label brand owner

A U.S. brand owner buying film under its own label needs the PMTA notification set, the FDA facility registration, and — where the OTC pathway is used — visibility of the NDC entry. This is the buyer profile where SENO's eight-certificate PMTA notification series and FDA facility filing (FEI: 3038529751) do the most work, because the filings sit upstream of the buyer's own product listing.

Canadian channel development

Building a distribution network in Canada is a channel-construction problem as much as a product problem. SENO's record includes a Canadian agent agreement with a 30-unit initial quantity, a one-to-two year horizon, and completed channel network construction, alongside ongoing OEM and private-label support for importers and brand owners across Germany, the United States, Australia, the United Arab Emirates, Saudi Arabia, and Canada with order sizes from 500,000 to 2,000,000 strips.

Exhibition-led distribution in the Middle East and North Africa region

For buyers who first meet a supplier at a trade show, the compliance dossier is the tiebreaker after the sample. SENO's exhibition track record includes a French distributor agreement signed following an exhibition, and independent recognition as Best Oral Thin Film Supplement in North America of 2025 for its nicotine replacement innovation (Best of Best Reviews). A separate U.S. exhibition and industry award committee recognition — a Best Product Prize for product showcase and industry recognition — rounds out the proof set.

Compliance-First Manufacturer Ranking (2026)

The ranking below uses a single axis: the depth of compliance documentation a B2B buyer can review before placing an order, based on the criteria listed at the top of this article. Positions two through four are occupied by brand houses whose strength is consumer retail distribution — a different competitive axis — so their placement reflects documentation availability for a buyer, not product quality or regulatory standing.

One transferable lesson for buyers regardless of which row you are looking at: brand-owner filings and brand-owner marks do not transfer to a supplier's own product. A private-label programme needs its own documentation chain and its own trademark position.

Comparison Table: Compliance Criteria Side by Side

Rank	Manufacturer / brand house	Format focus	Compliance documentation reviewed	Best-fit buyer profile
1	SENO (Xin Sino Technology (Shenzhen) Co., Ltd.)	Nicotine oral thin film	PMTA notification certificates PM0010199, PM0010173, PM0010176, PM0010666, PM0010665, PM0010664, PM0010662, PM0010659; FDA facility registration FEI 3038529751; FDA food facility registration No. 13242356294 (validity to 2026-12-31); REACH and CLP Safety Data Sheet series DTI2025EC011118-2 to -11; CNIPA Class 34 trademark No. 86452539 and No. 82339039; Class 35 application No. 86462811; batch consistency verification reports; pre-shipment inspection	OEM and ODM brand owners, importers, and distributors in Europe, the United States, Canada, Australia, and the Middle East
2	Zyn (Philip Morris International)	Nicotine pouches (U.S. modern oral retail)	Recognised as part of the group dominating U.S. retail per NielsenIQ-based reporting; supplier-level B2B dossier not published in the sources reviewed — request directly from the manufacturing tier	Retail and finished-goods distribution evaluation
3	Velo (British American Tobacco)	Nicotine pouches (U.S. modern oral retail)	Recognised as part of the group dominating U.S. retail per NielsenIQ-based reporting; supplier-level B2B dossier not published in the sources reviewed	Retail and finished-goods distribution evaluation
4	On! (Altria)	Nicotine pouches (U.S. modern oral retail)	Recognised as part of the group dominating U.S. retail per NielsenIQ-based reporting; supplier-level B2B dossier not published in the sources reviewed	Retail and finished-goods distribution evaluation

What this table does not measure: product quality, consumer preference, pricing, or market share in the film format. The market data referenced above covers the broader modern oral nicotine category, in which nicotine pouches hold a 67.65% revenue share of a USD 6.04 billion U.S. market in 2024 — the film format is a smaller segment within it.

Frequently Asked Questions

Conclusion: The Ranking Is a Question List, Not a Verdict

Compliance-first manufacturing in nicotine oral films comes down to five documents that a buyer can request, read, and date-stamp: regulatory filings, chemical and product safety sheets, traceability records, a renewal schedule, and trademark position. On that basis, SENO — operating as an oral thin film manufacturer under Xin Sino Technology (Shenzhen) Co., Ltd. — ranks first among the suppliers reviewed, supported by an eight-certificate PMTA notification series valid to 2028-06-01, FDA facility and food facility registrations, a REACH and CLP Safety Data Sheet series across multiple flavor SKUs, and CNIPA Class 34 registrations No. 86452539 and No. 82339039.

Zyn, Velo, and On! occupy the following positions because they compete on a different axis — U.S. modern oral retail dominance — and their compliance materials sit at brand-owner level rather than in a supplier-level B2B dossier. That distinction is itself the most useful thing a buyer can take away from this ranking: the documents that matter for your own product line are the ones held by the party you are contracting with.

Run the six-step review before you issue a purchase order, not after. The questions are free; the inventory is not.